Abstracts tagged "Autoantibody(ies)"

Abstract Number: 2265 • ACR Convergence 2022
Autoimmune RNA Dysregulation and Seizures: Therapeutic Prospects in Neuropsychiatric Systemic Lupus Erythematosus
Henri Tiedge¹, ILHAM MUSLIMOV², Valerio Berardi², Stacy Stephenson³, Ellen M. Ginzler⁴, Anca Askanase⁵ and John Hanly⁶, ¹SUNY, Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Medical Center, Brooklyn, NY, ³SUNY Downstate Medical Center, dep. of Comparative Medicine, Brooklyn, NY, ⁴SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ⁵Columbia University Medical Center, New York, NY, ⁶Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Neuropsychiatric (NP) involvement is common in systemic lupus erythematosus (SLE). Manifestations often include seizures and cognitive impairment but underlying etiology remains poorly understood. Brain…
Abstract Number: 0162 • ACR Convergence 2022
Clinical Features Associated with the Presence of anti-SSA/Ro60 Antibodies in anti-Jo-1 Antibody-positive Myositis
Koichi Yamaguchi¹, Qi Tang², Paul Poland³, Rohit Aggarwal⁴, Chester Oddis⁵ and Dana Ascherman⁵, ¹Gunma University Graduate School of Medicine, Maebashi, Japan, ²Second Xiangya Hospital of Central South University, Changsha, China, ³University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Anti-SSA antibodies target two unrelated proteins, Ro52 (E3 ligase) and Ro60 (RNA binding protein), that have different subcellular locations. Previous studies have indicated that…
Abstract Number: 0671 • ACR Convergence 2022
Thrombocytopenia and Autoimmune Hemolytic Anemia in Antiphospholipid Antibody-positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Zeynep Belce Erton¹, Rebecca K.Leaf², Danieli Castro Oliveira de Andrade³, Megan Barber⁴, Maria G. Tektonidou⁵, Vittorio Pengo⁶, Savino Sciascia⁷, Amaia Ugarte⁸, H Michael Belmont⁹, Chary López-Pedrera¹⁰, Paul R Fortin¹¹, maria gerosa¹², Guilherme de Jesús¹³, Tatsuya Atsumi¹⁴, ZHUOLI ZHANG¹⁵, Hannah Cohen¹⁶, D. Ware Branch¹⁷, Denis WAHL¹⁸, Laura Andreoli¹⁹, Esther Rodriguez Almaraz²⁰, Michelle Petri²¹, Ricard Cervera²², Yu (Ray) Zuo²³, Bahar Artim-Esen²⁴, ²⁵, Rohan Willis²⁶, Maria Laura Bertolaccini²⁷, Robert Roubey²⁸, Doruk Erkan¹ and on behalf of APS ACTION On Behalf Of APS ACTION¹, ¹Hospital for Special Surgery, New York, NY, ²Massachusetts General Hospital, Boston, MA, ³Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵National and Kapodistrian University of Athens, Athens, Greece, ⁶Padova University Hospital, Padova, Italy, ⁷University of Turin, Torino, Italy, ⁸BioCruces Bizkaia Health Research Institute, Barakaldo, Spain, ⁹NYU School of Medicine, New York, NY, ¹⁰Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, ¹¹Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, ¹²University of Milan, Milano, Italy, ¹³Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁴Hokkaido University, Sapporo, Japan, ¹⁵Peking University First Hospital, Beijing, China, ¹⁶University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁷University of Utah, Salt Lake City, UT, ¹⁸University of Lorraine, Nancy, France, ¹⁹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ²²Hospital Clinic Barcelona, Barcelona, Spain, ²³University of Michigan, Ann Arbor, MI, ²⁴Istanbul University, Istanbul, Turkey, ²⁵Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ²⁶University of Texas Medical Branch, Galveston, TX, ²⁷King's College London, London, United Kingdom, ²⁸University of North Carolina, Chapel Hill, NC
Background/Purpose: The APS ACTION Registry was created to study the natural course of antiphospholipid syndrome (APS) over 10 years in persistently antiphospholipid antibody (aPL) positive…
Abstract Number: 0987 • ACR Convergence 2022
A Randomized Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Systemic Lupus Erythematosus and Other Autoantibody-Associated Diseases
Stacey Dillon¹, Pille Harrison², Jason Lickliter³, Kristi Manjarrez¹, Alina Smith¹, Mary Lessig¹, Lori Blanchfield¹, Russell Sanderson¹, Allison Chunyk¹, Tiffany Blair¹, Amanda Enstrom¹, Martin Wolfson¹, Mark Rixon¹, Hany Zayed⁴, Rupert Davies¹ and Stanford Peng¹, ¹Alpine Immune Sciences, Seattle, WA, ²Alpine Immune Sciences, Taunton, United Kingdom, ³Nucleus Network, Melbourne, Australia, ⁴Alpine Immune Sciences, San Francisco, CA
Background/Purpose: B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are tumor necrosis factor (TNF) superfamily members that bind TACI (transmembrane activator and CAML…
Abstract Number: 1472 • ACR Convergence 2022
Autoantibodies Against Tripartite-Motif 72 Protein (TRIM72) in Systemic Lupus Erythematosus Patients and in a Lupus Mouse Models with Myocarditis, Can Compromise Membrane Repair in Cardiomyocytes Potentially Contributing to Cardiovascular Disease Progression
Kassidy Banford¹, hannah Bulgart¹, Shane Bruckner², Stacy Ardoin³, Noah Weisleder² and Wael Jarjour², ¹The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University, Columbus, OH, ³The Ohio State College of Medicine, Columbus, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that typically manifests in multiple organs, with some of the most significant complications occurring in the…
Abstract Number: 1946 • ACR Convergence 2022
Focused Clinical Correlation of Autoantibody Testing in Juvenile Systemic Sclerosis and Localized Scleroderma Using the Euroimmun™ Scleroderma Disease Profile
Jonathan Li¹, Emily Mirizio², Katherine Buhler³, Anne Stevens⁴, May Choi⁵, Kaila Schollaert-Fitch², Kathryn Torok², Christopher Liu² and Marvin Fritzler³, ¹Combined Internal Medicine-Pediatrics Residency Program, Children's Hospital of UPMC, Pittsburgh, PA, ²Pediatric Rheumatology, Children's Hospital of UPMC, Pittsburgh, PA, ³University of Calgary, Calgary, AB, Canada, ⁴Janssen, Hansville, WA, ⁵Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: Commercially available autoantibody (AAb) panels are developed for adult rheumatological diseases; application to pediatric disease has not been established. As a pediatric scleroderma referral…
Abstract Number: 0166 • ACR Convergence 2022
Detection of the Novel Autoantibodies Against Transcription Factor Sp4 Is Related with Low Risk of Cancer in Idiopathic Inflammatory Myopathy Patients
Yuji Hosono¹, Azusa Kojima¹, Akira Ishii¹, Mai Sugiyama¹, Yuto Izumi¹, Noriko Sasaki², Chiho Yamada¹ and Shinji Sato¹, ¹Tokai University School of Medicine, Isehara Kanagawa, Japan, ²Tokai University School of Medicine, sagamihara-city, Japan
Background/Purpose: In idiopathic inflammatory myopathy (IIM), many kinds of autoantibodies are often detected and associated with each clinical phenotype. Recently, autoantibody against transcription factor Sp4…
Abstract Number: 0683 • ACR Convergence 2022
ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases: Clinical and Serological Characteristics, Results from the APS ACTION Clinical Database and Repository
Irene Cecchi¹, Massimo Radin², Silvia Grazietta Foddai², Maria Laura Bertolaccini³, Danieli De Andrade⁴, Maria Tektonidou⁵, Vittorio Pengo⁶, Guillermo Ruiz-Irastorza⁷, H. Michael Belmont⁸, Maria Gerosa⁹, Paul Fortin¹⁰, Chary Lopez-Pedrera¹¹, Zhouli Zhang¹², Tatsuya Atsumi¹³, Guilherme de Jesus¹⁴, Hannah Cohen¹⁵, Nina Kello¹⁶, Ware Branch¹⁷, Denis Wahl¹⁸, Laura Andreoli¹⁹, Esther Rodriguez²⁰, Michelle Petri²¹, Megan R.W. Barber²², Ricard Cervera²³, Jason Knight²⁴, Bahar Artim-Esen²⁵, Rohan Willis²⁶, Guillermo Pons-Estel²⁷, Doruk Erkan²⁸ and Savino Sciascia¹, ¹University of Turin, Torino, Italy, ²University of Turin, Turin, Italy, ³King's College London, London, United Kingdom, ⁴University of São Paulo, São Paulo, Brazil, ⁵University of Athens, Athens, Greece, ⁶University of Padova, Padova, Italy, ⁷University of the Basque Country, Barakaldo, Spain, ⁸New York University School of Medicine, New York, NY, ⁹University of Milan, Milano, Italy, ¹⁰CHU de Québec Université Laval, Québec, QC, Canada, ¹¹Hospital Universitario Reina Sofía, Cordoba, Spain, ¹²Beijing Medical University, Beijing, China, ¹³Hokkaido University, Sapporo, Japan, ¹⁴Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁵University College London, London, United Kingdom, ¹⁶Northwell Health, New York, NY, ¹⁷University of Utah Health, Salt Lake City, ¹⁸Nancy University Hospital, Nancy, France, ¹⁹University of Brescia, Brescia, Italy, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Johns Hopkins University School of Medicine, Baltimore, MD, ²²University of Calgary, Calgary, AB, Canada, ²³University of Barcelona, Barcelona, Spain, ²⁴University of Michigan, Ann Arbor, MI, ²⁵Istanbul University, Istanbul, Turkey, ²⁶University of Texas, Galveston, TX, ²⁷Centro Regional de Enfermedades Autoinmunes y Reumáticas, Rosario, Argentina, ²⁸Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: APS ACTION is an international Clinical Database and Repository of persistently antiphospholipid antibody (aPL)-positive subjects, collecting demographic, medical history, and aPL data.This study focused…
Abstract Number: 1048 • ACR Convergence 2022
Nailfold Capillaroscopy and Candidate Biomarker Levels in Systemic Sclerosis-associated Pulmonary Hypertension, Profiling of Non-invasive Markers: A Cross Sectional Study
Jacqueline Lemmers¹, Arjan van Caam², Brigit Kersten², Els Ende, van den², Hanneke KNAAPEN², Arie Dijk, van², Wanda Hagmolen of ten Have², Frank van den Hoogen², Hans Koenen², Sander van Leuven³, wynand Alkema⁴, Ruben Smeets² and Madelon Vonk⁵, ¹Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands, ²Radboudumc, Nijmegen, Netherlands, ³Radboud University, Nijmegen, Netherlands, ⁴Hanze University, Groningen the Netherlands, Dept. Data Science for Life Sciences & Health, Groningen, Netherlands, ⁵Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Pulmonary hypertension (PH) is one of the leading causes of death in Systemic Sclerosis (SSc). Early detection and treatment of PH in SSc is…
Abstract Number: 1476 • ACR Convergence 2022
Anti-Neutrophil Extracellular Traps (NET) Antibodies and Their Association with Disease Activity and Clinical Phenotypes in Systemic Lupus Erythematosus
Rosa Arvizu-Rivera¹, jiram torres-Ruiz², Alfredo Pérez-Fragoso², Beatriz Alcalá-Carmona³, Miroslava Nuñez-Aguirre⁴, Ana Sofía Vargas-Castro⁴, Abdiel Absalón-Aguilar³, Jaquelin Lira-Luna⁴ and Diana Gómez-Martín², ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico, ²INCMNSZ, Ciudad de México, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ⁴Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico
Background/Purpose: Enhanced netosis has been acknowledged as pathogenic in Systemic Lupus Erythematosus (SLE). The presence of antibodies against neutrophil extracellular traps (anti-NETs) in patients with…
Abstract Number: 1965 • ACR Convergence 2022
Autoantibodies Against a Specific 25-mer Peptide from P. Gingivalis Are Present in Sera of Patients with Rheumatoid Arthritis and Early Arthritis
Hsin-Yi Peng¹, Ting-Yin Xue¹, Fei-Hung Hsieh¹, Yi-Ko Chen¹, Mei-Chin Yin², Che-Yi Chao², Shu-Yao Tsai², Chung-Ping Lin³, Po-Hao Huang³, Chien-Chung Huang³, Jiunn-Horng Chen³, Chung-Ming Huang³, Der-Yuan Chen⁴, Joung-Liang Lan⁵ and Gregory Tsay³, ¹China Medical University, Taichung, Taiwan, ²Asia University, Taichung, Taiwan, ³China Medical University Hospital, Taichung, Taiwan, ⁴China Medical University Hospital Rheumatology and Immunology Center, Taichung, Taiwan, ⁵China Medoical University Hospital, Taichung, Taiwan
Background/Purpose: The presence of rheumatoid factor (RF) or anti-cyclic citrullinated protein/peptide antibodies (ACPA) are included in the 2010 the ACR/EULAR classification criteria of rheumatoid arthritis…
Abstract Number: 0167 • ACR Convergence 2022
Accuracy of Multi-Centric Local Determination of Anti-Synthetase Autoantibodies in Patients with Anti-Synthetase Syndrome and Other Autoimmune Diseases
Giovanni Zanframundo¹, Angela Ceribelli², Sara Faghihi Kashani³, Monica Morosini⁴, Sara Bozzini⁵, Natasa Isailovic⁶, Carlo Selmi⁷, Lorenzo Cavagna⁸ and Rohit Aggarwal⁹, ¹Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Milano, Italy, ²Humanitas Research Hospital, Humanitas University, Rozzano (MI) Italy, Borgo San Giacomo, Italy, ³Stanford University, Stanford, CA, ⁴Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, ⁵Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, ⁶IRCCS Humanitas Research Hospital, Rozzano (MI), Italy, Rozzano, Italy, ⁷IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy, Rozzano, Italy, ⁸Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, ⁹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: RNA-immunoprecipitation (RNA-IP) is considered the gold standard method for anti-tRNA synthetase antibodies (ARS-Ab) detection. This technique, however, is not widely available, unlike commercial kits,…
Abstract Number: 0684 • ACR Convergence 2022
Single Antiphospholipid Antibody Positive Thrombotic APS Patients’ Clinical Characteristics: Retrospective Results from the APS ACTION Clinical Database and Repository (Registry)
Silvia Grazietta Foddai¹, Irene Cecchi², Massimo Radin¹, Danieli De Andrade³, Maria Tektonidou⁴, Vittorio Pengo⁵, Guillermo Ruiz-Irastorza⁶, H. Michael Belmont⁷, Maria Gerosa⁸, Paul Fortin⁹, Rosario Lopez-Pedrera¹⁰, Zhouli Zhang¹¹, Tatsuya Atsumi¹², Guilherme de Jesus¹³, Hannah Cohen¹⁴, Nina Kello¹⁵, Ware Branch¹⁶, Denis Wahl¹⁷, Laura Andreoli¹⁸, Esther Rodriguez¹⁹, Michelle Petri²⁰, Ann E. Clarke²¹, Ricard Cervera²², Jason Knight²³, Bahar Artim-Esen²⁴, Rohan Willis²⁵, Guillermo Pons-Estel²⁶, Doruk Erkan²⁷, Dario Roccatello¹ and Savino Sciascia², ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy, ³University of São Paulo, São Paulo, Brazil, ⁴University of Athens, Athens, Greece, ⁵University of Padova, Padova, Italy, ⁶University of the Basque Country, Barakaldo, Spain, ⁷New York University School of Medicine, New York, NY, ⁸University of Milan, Milano, Italy, ⁹CHU de Québec Université Laval, Québec, QC, Canada, ¹⁰University of Cordoba, Cordoba, Spain, ¹¹Beijing Medical University, Beijing, China, ¹²Hokkaido University, Sapporo, Japan, ¹³Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁴University College London, London, United Kingdom, ¹⁵Northwell Health, New York, NY, ¹⁶University of Utah Health, Salt Lake City, ¹⁷Nancy University Hospital, Nancy, France, ¹⁸University of Brescia, Brescia, Italy, ¹⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁰Johns Hopkins University School of Medicine, Baltimore, MD, ²¹University of Calgary, Calgary, AB, Canada, ²²University of Barcelona, Barcelona, Spain, ²³University of Michigan, Ann Arbor, MI, ²⁴Istanbul University, Istanbul, Turkey, ²⁵University of Texas, Galveston, TX, ²⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas, Rosario, Argentina, ²⁷Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: The APS ACTION is a network collecting and analyzing data ofaPL positive patients recruited by international centers. Based on the assumption that triple aPL-positive…
Abstract Number: 1068 • ACR Convergence 2022
Anti-vinculin Antibodies in Systemic Sclerosis: Associations with Slow Gastric Transit and Extra-Intestinal Clinical Phenotype
Maria Herran¹, Brit Adler², Jamie Perin³, Walter Morales⁴, Mark Pimentel⁵ and Zsuzsanna McMahan⁶, ¹School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia, ²Johns Hopkins University, Division of Rheumatology, Baltimore, MD, ³John Hopkins University, Baltimore, MD, ⁴Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, ⁵Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai, Los Angeles, CA, ⁶Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: The gastrointestinal tract is commonly affected in systemic sclerosis (SSc). Prior studies have reported an association between higher levels of anti-vinculin antibodies and gastrointestinal…
Abstract Number: 1523 • ACR Convergence 2022
Anti-RNPC3 Autoantibodies in Mixed Connective Tissue Disease Are Associated with Systemic Sclerosis Skin Involvement
Darya S. Jalaledin¹, Hajar El Kamouni², Alexandra Albert³, Sabrina Hoa⁴, Josiane Bourre-Tessier⁵, Eric Rich⁵, Jean-Richard Goulet⁶, Martial Koenig⁷, Minoru Satoh⁸, Marvin Fritzler⁹, May Choi¹⁰, Yves Troyanov¹¹, Jean-Luc Senécal, MD¹² and Océane Landon-Cardinal⁵, ¹Division of Internal Medicine, Centre Hospitalier de l'Université de Sherbrooke, Saint-Lambert, Canada, ²Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Laval, Canada, ³Division of Rheumatology, Centre Hospitalier de l'Université Laval, Québec, QC, Canada, ⁴University of Montreal, Montréal, QC, Canada, ⁵Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁶Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Saint-Lambert, Canada, ⁷Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁸Department of Human, Information and Science, University of Occupational Environmental Health, Kitakyusyu Fukuoka, Japan, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ¹¹Division of Rheumatology, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, ¹²Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Montréal, Canada
Background/Purpose: RNA-binding region containing 3 (RNPC3) protein acts as a molecular bridge, promoting U11/U12 RNP complex formation. In previous studies, systemic sclerosis (SSc) patients who…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].